An interventional study of Culturally Targeted Narrative Video: "Is My Cancer Hereditary? Rosa Visits a Genetic Counselor." and FORCE Fact Sheet in Hereditary Breast and Ovarian Cancer, sponsored by Georgetown University. Completed at 2 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Georgetown University · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Hereditary Breast and Ovarian Cancer Syndrome · United States.
Among the 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States, this one is the 7th largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2021, is one of 17 with no phase, and was the 29th registered.
62 studies on the registry are indexed under Hereditary Breast and Ovarian Cancer Syndrome; 13 are open to participants now.
Browse Hereditary Breast and Ovarian Cancer Syndrome studies →7 of the 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 35+ · Women only
Georgetown University · Sites in United States
Ages 18–74 · Women only
OHSU Knight Cancer Institute · Sites in United States
Ages 18+ · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
University of Kansas Medical Center · Sites in United States
Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 10 Hereditary Breast and Ovarian Cancer Syndrome studies recruiting now, 7 (70%) set no upper age limit and 1 (10%) stops at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 289 is above the median of 150 across 43 interventional studies indexed under Hereditary Breast and Ovarian Cancer Syndrome.
Median enrollment 157 across the 23 interventional studies, 440 across the 12 observational. Of the 24 that completed or were terminated, 4 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 35 have an industry lead sponsor. The 10 most frequent:
Georgetown University is the lead sponsor of 292 studies on the registry; 40 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 20 (71%) have results posted.
Georgetown University has 6 studies filed under Hereditary Breast and Ovarian Cancer Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02302742University of Kansas Medical CenterTriple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry | 2026-12 |
| NCT06892275Georgetown UniversityThe FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI | 2027-06 |
| NCT05677048M.D. Anderson Cancer CenterFeasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 35 studies in Hereditary Breast and Ovarian Cancer Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a mixed-methods Hybrid Type 1 research design (efficacy study) in which we aim to conduct a two-arm randomized controlled trial and an Implementation Focused Process Evaluation of a culturally-targeted video and referral screening tool.
In this study, the investigators aim to evaluate the efficacy of a culturally targeted video previously developed by the research team vs. a Spanish-language fact sheet from an established group on enhancing genetic counseling and testing uptake and psychosocial outcomes in Latina women at risk for hereditary breast and ovarian cancer.
The investigators will test the video's efficacy while also gathering data on the implementation and future sustainability of using the Risk Screening Tool (RST) and video in community clinics.
The investigators previously developed and piloted a culturally targeted narrative video in Spanish to provide HBOC and GCT education to at-risk Latinas. The investigators expanded traditional approaches to address psychosocial barriers through risk messages designed to elicit emotional responses; emotions are often stronger predictors of behavior than cognition. Our video is responsive to Latinas' preferences, targets motivators, and addresses psychosocial barriers identified in our formative research.
In this study, the investigators aim to evaluate the efficacy of our video vs. a fact sheet from an established group on enhancing GCT uptake and psychosocial outcomes on a two-arm randomized controlled trial. The investigators will test the video's efficacy while also gathering data on the implementation and future sustainability of using an adapted Risk Screening Tool (RST) and video in community clinics.
The investigators will partner with community clinics and implement a Risk Screening Tool (RST) at their practice to identify women at risk of HBOC. Community clinic staff (N\~32) will be asked to participate in a pre-implementation and a post-implementation focus group to assess implementation outcomes of integrating HBOC screening practices in their clinic. Through the community clinics, the investigators aim to recruit N\~300 Latina women at risk for HBOC based on their personal or family history of cancer. Latina women at risk for HBOC will be randomized to a Video arm or Fact Sheet Arm. All participants in the randomized controlled trial will be offered genetic counseling and testing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Aim 1 and 2.
Aim 3.
Exclusion Criteria:
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Culturally Targeted Narrative Video: "Is My Cancer Hereditary? Rosa Visits a Genetic Counselor." Participants in the video arm will be asked to watch an 18-minute video that the research team developed and tested previously about HBOC and genetic services. The video is recorded with Spanish audio and is available with English subtitles.
Behavioral: Culturally Targeted Narrative Video: "Is My Cancer Hereditary? Rosa Visits a Genetic Counselor."
Participants in the Fact Sheet arm will receive a Fact sheet about HBOC and genetic services and will be asked to read it in their own time. The Fact Sheet is available in English and Spanish.
Behavioral: FORCE Fact Sheet
Participants randomized to the video arm will receive a link with a password by email or text message to watch the video, depending on participants' preference. Participants without internet access will receive a DVD. Participants will be instructed to watch the video alone with no interruptions. We will ask them not to share the link with others.
Participants will receive a PDF of the fact sheet by email, text message, or a printed fact sheet by mail depending on participants' preferences. The fact sheet includes information about genes, breast cancer, risk factors for HBOC, genetic counseling and testing, and resources.
Uptake of Genetic Counseling
Participants will self report whether they attended a genetic counseling session in the four months following their baseline survey. The study team will also have direct access to the genetic counseling company's records.
Time frame: Change from the baseline survey to four months after baseline
Uptake of Genetic Testing
Participants will self report whether they completed a genetic test for hereditary cancer in the four months following their baseline survey. The study team will also have direct access to the genetic counseling company's records.
Time frame: Change from the baseline survey to four months after baseline
Knowledge about HBOC
9-item Scale from Kasting et al, 2019. The scale has statements to which participants respond True, False, or I don't Know. The scale is scored based on the accuracy of responses. A higher score indicates higher knowledge. Scores range from 0-9.
Time frame: Change from the baseline to two-week after baseline, and change from two-week follow up survey to four months after baseline
Self-efficacy about attending genetic cancer risk assessment
Change in self-efficacy about genetic counseling and testing will be measured by specific items from the Theory of Planned Behavior scale (Ajzen, 2002) on a scale from 1-7 -Not at all to 7- Extremely)
Time frame: Change from the baseline to two-week after baseline
Beliefs and Attitudes about genetic cancer risk assessment
Changes in beliefs and attitudes about genetic counseling and genetic testing. The outcome will be assessed by 22 items from a scale developed by Sussner, Jandorf, Thompson et al., 2012 in which participants respond to a Likert-type scale from 1 (completely disagree) to 7 (completely agree).
Time frame: Change from the baseline to two-week after baseline
Subjective norms about genetic cancer risk assessment
Change in subjective norms about genetic counseling and testing will be measured by specific items from the Theory of Planned Behavior scale (Ajzen, 2002) on a scale from 1-Not at all to 7- Extremely)
Time frame: Change from the baseline to two-week after baseline
Anticipatory emotions about genetic cancer risk assessment
Scale items on a 7-point Likert-type response (from 1-strongly disagree to 7-strongly agree).
Time frame: Change from the baseline to two-week after baseline
Acceptability of the intervention
Overall acceptability is measured on a 4-item self-reported scale ranging from 1 to 10, where 1 = not at all to 10 = highly
Time frame: At two weeks after baseline
Feasibility of the intervention
Proportion of women who have watched/read the video or fact sheet at the two week follow up
Time frame: At two weeks after baseline
Feasibility of the Referral Screening Tool
Qualitative measure captured through semi-structured interviews using the Consolidated Framework for Implementation Research. (e.g., What barriers and facilitators did you experience while implementing the RST?)
Time frame: Change from the pre-implementation focus groups with community clinics to post implementation focus groups with community clinics (48 months)
Acceptability of the Referral Screening Tool
Qualitative measure captured through semi-structured interviews using the Consolidated Framework for Implementation Research.
Time frame: Change from the pre-implementation focus groups with community clinics to post implementation focus groups with community clinics (48 months)
Adoption of the Referral Screening Tool
Qualitative measure captured through semi-structured interviews using the Consolidated Framework for Implementation Research.
Time frame: At the post implementation focus groups with community clinics adoption over the previous 48 months will be assessed
Sustainability of the Referral Screening Tool
Qualitative measure captured through semi-structured interviews using the Consolidated Framework for Implementation Research.
Time frame: At the post implementation focus groups with community clinics sustainability of the screener based on their experience during the previous 48 months will be assessed
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2021 to primary completion in Jun 2026, 60 months.
Of 23 interventional studies with no phase under Hereditary Breast and Ovarian Cancer Syndrome, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 31. This study's 60 months is close to that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 3, 2026: primary completion Dec 2025 → Jun 2026 and completion Dec 2025 → Jun 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hereditary Breast and Ovarian Cancer Syndrome →